ライフサイエンスコーパス: crossover design

1 nmol or 1150 mg) amounts of sodium for 30 d (crossover design).

2 randomized, double-blind, single-dose, 4-way crossover design.

3 ia using a double-blind, placebo-controlled, crossover design.

4 olol used a double-blind, placebo-controlled crossover design.

5 acebo, on separate mornings, in a randomized crossover design.

6 condition were determined using a randomized crossover design.

7 re fed each of 3 healthy diets for 6 wk in a crossover design.

8 n MC (35% carbohydrate) diet-randomized in a crossover design.

9 tudy used a randomized, double-masked, 2 x 2 crossover design.

10 ouble-blind, placebo-controlled, randomized, crossover design.

11 tered 3 meals in a randomized, double-blind, crossover design.

12 s for 6-wk periods according to a randomized crossover design.

13 andomized, double-blind, placebo-controlled, crossover design.

14 acebo, on separate mornings, in a randomized crossover design.

15 ed with each of 4 diets in random order in a crossover design.

16 mg) or saline in a randomized, double-blind, crossover design.

17 med by using a linear model for a two-period crossover design.

18 vehicle) every 2 weeks for 1 month each in a crossover design.

19 dapiprazole in a double-masked, randomized, crossover design.

20 e occasions in a single-blind, random order, crossover design.

21 ssignments were random and double blind in a crossover design.

22 ts aged 25-56 y participated in a randomized crossover design.

23 rating the treatment periods in a randomized crossover design.

24 tructured critical care elective, by using a crossover design.

25 te (HC) or high-fat (HF) diet according to a crossover design.

26 antarflexion using a prospective, randomized crossover design.

27 disease to consume black tea and water in a crossover design.

28 tmenopausal women in a 4-treatment, 4-period crossover design.

29 ets assigned by using a randomized, balanced crossover design.

30 udents completed the other scenario, using a crossover design.

31 The investigation had a randomized, blinded, crossover design.

32 l meal and a strawberry meal in a randomized crossover design.

33 rs, using a double-blind, placebo-controlled crossover design.

34 low-fiber diet for 4 wk each in a randomized crossover design.

35 iets were consumed for 23 d in a randomized, crossover design.

36 h FTFI and V-CASI techniques in a randomized crossover design.

37 ate occasions in a single-blind, randomized, crossover design.

38 a high-fat (46% fat) diet for 6 wk each in a crossover design.

39 n and nonvegetarian diets for 8 wk each in a crossover design.

40 ed in 15 healthy volunteers in a randomized, crossover design.

41 cebo for 8 wk in a randomized, double-blind, crossover design.

42 dure, separated by 1 week, in a double-blind crossover design.

43 confirm this finding by using a double-blind crossover design.

44 ed two amino acid mixtures in a double-blind crossover design.

45 clinical trial performed with an open-label crossover design.

46 or low glycogen (LG) stores in a randomized crossover design.

47 at two dietary calcium intakes with use of a crossover design.

48 Seven lean, male subjects were studied in a crossover design.

49 rst or the second 15-d residency period in a crossover design.

50 g asthmatics using an open-label, randomized crossover design.

51 high-fat and low-fat diet administered in a crossover design.

52 double-blind, placebo-controlled, randomized crossover design.

53 diet (5% of total daily energy intake) in a crossover design.

54 g pectin/d) in a prospective, single-blind, crossover design.

55 -30 to 240 min) in a double-blind randomized crossover design.

56 ng using a placebo-controlled, double-blind, crossover design.

57 g a double-blind placebo-controlled balanced crossover design.

58 r 0.4 mg doses) in a randomized double-blind crossover design.

59 e of a dual-center, single-blind, randomized crossover design.

60 4 separate days with the use of a randomized crossover design.

61 pram (10 mg) intravenously in a double-blind crossover design.

62 udy was a randomized controlled trial with a crossover design.

63 ate occasions in a double-blind, randomized, crossover design.

64 ented to 98 healthy subjects in a randomized crossover design.

65 diet versus a LOWCAL diet using a randomized crossover design.

66 K561679 (high-GSK), and 1 mg alprazolam in a crossover design.

67 ing after short-term SSRI exposure by a case-crossover design.

68 -5 (BACE inhibitor) or vehicle in a four-way crossover design.

69 lic syndrome patients following a randomized crossover design.

70 scanned repeatedly in a placebo-controlled, crossover design.

71 TANOC and (68)Ga-DOTATATE using a randomized crossover design.

72 ch (hyperhedonia) using functional MRI and a crossover design.

73 ndomized, counter-balanced, within-subjects, crossover design.

74 efully consider the length of washout within crossover designs.

75 at incorporate noninferiority, factorial and crossover designs.

76 In a crossover design, 10 healthy volunteers were served beer

77 double-blind, randomized, repeated measures, crossover design, 11 cyclists consumed a placebo or caff

78 In a crossover design, 12 subjects with schizophrenia were st

79 In a randomized crossover design, 15 healthy volunteer consumed 100g of

80 In a placebo-controlled, within-subject, crossover design, 16 healthy human subjects performed a

81 In an open, 3-way, randomized crossover design, 18 healthy volunteers ingested felodip

82 In a crossover design, 20 healthy older men [aged 65-85 y] we

83 In a crossover design, 24 young women were provided with meal

84 mol/L, patients consumed, in a double-blind, crossover design, 250 mg caffeine or matched placebo.

85 In a crossover design, 3- to 5-y-old children in a daycare ce

86 In a double-blind, randomized, crossover design, 30 healthy subjects performed two iden

87 Utilizing a double-blind, placebo-controlled crossover design, 35 fathers and their 5-month-old infan

88 Using a crossover design, a 12-hr pharmacokinetic study was then

89 were studied on 3 occasions in a randomized, crossover design after 6 d of dietary intervention.

90 The 3-period crossover design allowed for meaningful and efficient co

91 ns in clinical trial design such as parallel crossover design, alternative endpoints, or adaptive tri

92 l studies-3 with a randomized, double-masked crossover design and 1 with 4 parallel crossover studies

93 We used a triple-crossover design and a composite of three outcomes (exac

94 Case-crossover design and conditional logistic regression to

95 All experiments used the same crossover design and followed similar experimental proce

96 The study had a crossover design and included 43 healthy men aged 19-56

97 We used a crossover design and thermal stimuli on uninjured skin t

98 We used a time-stratified case-crossover design, and conditional logistic regression mo

99 reatments were administered to subjects in a crossover design, and diets contained 1 of 3 almond dose

100 /kg, 2 mg/kg) in a double-blind, randomized, crossover design, and exercise challenge was performed 4

101 A double-blind, placebo-controlled, crossover design approach was used in abstinent alcohol

102 onditions in a double-blind, random-ordered, crossover design, approximately 1 week apart.

103 -controlled case series method, and the case-crossover design, are described and summarized in tabula

104 ation was a randomized clinical trial with a crossover design at a nonprofit eye research institute.

105 tACS was applied using a sham-controlled crossover design at individualized intensity for 20 min

106 This study used a morning x evening light crossover design balanced by parallel-group controls, in

107 , placebo-controlled design; 2) absence of a crossover design between patient groups; 3) mean follow-

108 All studies used randomized crossover design comparing CSII versus CLC during identi

109 were studied in a randomized, double-blind, crossover design comparing tryptophan depletion to a pla

110 4) were then tested twice, in a double-blind crossover design, comparing either: (1) placebo vs 10 mg

111 in a 2-drug, double-blind placebo-controlled crossover design conducted from January 21, 2009, to Sep

112 eived four breakfasts following a randomised crossover design consisting of different oils (virgin ol

113 The randomized crossover design corroborates that vALIC DBS causes symp

114 eg, randomized controlled trials, randomized crossover designs), could revolutionize the conduct of r

115 andomized, double-blind, placebo-controlled, crossover design, drug-free OCD adults (n=15) with near-

116 loric LF, LGI, and VLC diets in a randomized crossover design, each for a 4-week period of weight los

117 stradiol and progesterone in a double-blind, crossover design, each for four weeks, during continued

118 ents to one of four treatment sequences in a crossover design, each involving two 16-week treatment p

119 A double-blind 3-treatment crossover design employing a 6-day trial period with out

120 domized to the following 7-day regimens in a crossover design: enteric-coated aspirin 100 mg twice da

121 In a crossover design experiment, data from 12 patients were

122 rograms/kg/min) or placebo in a double-blind crossover design experiment.

123 e 3-month periods (randomized, double-blind, crossover design), followed by 6 additional pacing-on mo

124 twice in a double-blind, placebo-controlled crossover design, following either placebo or 40-mg oral

125 They used a case-crossover design for 135 case events occurring among 125

126 e a day) or placebo given in a double-blind, crossover design for two 18-week periods.

127 outcome-indexed self-controlled (i.e., case-crossover) designs for active surveillance and evaluate

128 Properties of the case-crossover design have appeal for investigation of acute

129 In a balanced, placebo-controlled crossover design, healthy volunteers (n=20) received a c

130 In a double-blind, crossover design, hyperuricemic CHF patients were random

131 chips ad libitum for an afternoon snack in a crossover design in two 10-d periods.

132 ment used a double-blind, placebo-controlled crossover design in which 50 mg of oral DHEA was adminis

133 We used a modified crossover design in which one half of a fellowship class

134 The case-crossover design, introduced in 1991 by Malcolm Maclure,

135 ETTING, AND PARTICIPANTS: A controlled 3-way crossover design involving 21 overweight and obese young

136 The case-crossover design is useful for assessing whether a recur

137 breakfast meals were tested in a randomized crossover design: low fiber, low fat; high fiber, low fa

138 ronic medication exposure by means of a case-crossover design may result in an upward-biased odds rat

139 In 2 experiments with crossover designs, men and women were served a meal of a

140 dental research application, the equivalence/crossover design methodology is shown to be an efficient

141 Using a randomized crossover design, National Survey of Family Growth (NSFG

142 In a 2-way crossover design, nonresponders (n=41) and responders (n

143 DESIGN, STUDY, AND PARTICIPANTS: A case-crossover design of 13,860 Medicare patients with AMI fr

144 We replicated the traditional crossover design of nutrition studies in a naturalistic

145 alance and kinetic modeling in a randomized, crossover design of three 1-mo controlled dietary interv

146 In a randomized crossover design, one study was performed with each form

147 randomization or change in dose assignment, crossover design, or protocol amendment, were included.

148 In a crossover design outpatient study, 12 adults aged 24-36

149 by active AMPH in a randomized, double-blind crossover design over 4 test days.

150 Unexpectedly, ketamine's effects within the crossover design showed significant (p<0.005) carryover

151 In a double-blind, order-balanced, crossover design, six healthy, trained men (normoxic VO2

152 A crossover design study in 16 men compared fasting and po

153 naurally in a planned comparison, randomized crossover design study with binaural broadband hearing i

154 randomized double-blinded placebo-controlled crossover design study, 12 patients received either a si

155 , or placebo in a double-blind, four-period, crossover design study.

156 dults in a double-blind, placebo-controlled, crossover designed study and then assessed memories of c

157 ects completed a randomized, double-blinded, crossover-design study in which they consumed either 5 o

158 ere randomized into a 16-week, double-blind, crossover-design study of clomipramine, a potent seroton

159 This randomized crossover-designed study tested the biological activity

160 uglycemic clamping (low FFA) in a randomized crossover-designed study.

161 In a crossover design, subjects consumed diets that supplied

162 In a crossover design, subjects undertook the alternate diet

163 e the treatment response objectively and the crossover design that allows estimating the treatment ef

164 We used a randomized crossover design that consisted of a 14-d fully controll

165 Next, using a within-subject, crossover design, the authors sampled CSF for 6 hours th

166 In a double-blind placebo-controlled crossover design, the immune system in 22 sample donors

167 In a randomized crossover design, the other labeled meal, which containe

168 ese participants were randomly assigned in a crossover design to 2 periods of a 4-wk hypocaloric diet

169 in cornstarches were fed for 14 wk each in a crossover design to 24 men [10 control, 14 hyperinsuline

170 This study used a prospective nested case-crossover design to compare the risk of ICD shock for VT

171 descent (n = 53) were randomly assigned in a crossover design to consume a Mexican or US diet for 24

172 aging in a double-blind, placebo-controlled, crossover design to determine how intranasally administe

173 We used the case-crossover design to determine whether apneas and/or hypo

174 nistered in a randomized, placebo-controlled crossover design to eight type 2 diabetic subjects and s

175 We used a time-stratified case-crossover design to estimate adjusted odds ratios for th

176 1992 through 2006 in a time-stratified case-crossover design to estimate the association between hos

177 on) + /- hydrocortisone (HC) in a randomised crossover design to produce low, medium and high glucoco

178 ess test were randomized in a double-masked, crossover design to receive a titrated intravenous infus

179 , patients were randomized in a double-blind crossover design to stimulation ON or OFF for 1-month pe

180 rial used a double-blind, placebo-controlled crossover design to study 73 children and adolescents ag

181 The authors used a case-crossover design to study the association between ambien

182 Our study used a crossover design to test to what extent insulin-induced

183 NA or combination therapy in an open-label, crossover design trial to assess the effects on serum li

184 ffects were consistent in parallel group and crossover design trials, and in analyses of dose-respons

185 tion age, population health, parallel versus crossover design, type of control oil, or study quality

186 was assessed by using a time-stratified case-crossover design using 11 677 emergency medical service-

187 re administered using a randomized, blinded, crossover design via a face mask and an inspiratory dema

188 A case-crossover design was applied to identify environmental r

189 A randomized crossover design was incorporated in which 20 girls [mea

190 A double-blind, placebo-controlled, crossover design was used to compare addition of 5 mg of

191 A randomized, crossover design was used to compare diets enriched with

192 A case-crossover design was used to compare the distributions o

193 A randomized, crossover design was used to compare the effects of a hi

194 A randomized crossover design was used to compare the effects on midd

195 A time-stratified case-crossover design was used to help control for time-invar

196 A case-crossover design was used to study 147,885 hospital admi

197 A single-blind, randomized, within-subject crossover design was used to study the effects of palm o

198 A randomized split-mouth crossover design was used with one quadrant of surgery i

199 A 10-week, two-treatment period, crossover design was used.

200 A double-blind, placebo-controlled crossover design was used.

201 A single-blind randomized crossover design was used.

202 A randomized, double-blind, 5-period, crossover design was used.

203 A three-period crossover design was utilised lasting 42 weeks, with thr

204 le-blind, placebo-controlled, within-subject crossover design we aimed to determine the effect of a s

205 In a randomized, counterbalanced, crossover design, we applied anodal tDCS (atDCS), cathod

206 Using case-crossover design, we compared the following exposure sta

207 double-blind, placebo-controlled, randomized crossover design, we determined the effects of dietary N

208 Using a case-crossover design, we examined the association of congest

209 Using a double-blind placebo-controlled crossover design, we pharmacologically increased synapti

210 In this open-label, multicenter trial with crossover design, we randomly assigned patients with new

211 randomized, double blind, placebo-controlled crossover design, we show that OT administration in ASD

212 Using a crossover design, we studied the effect of dialysis with

213 In a randomized, double-blind, crossover design, we studied the effects of high-dose (5

214 Here, in a randomized, counterbalanced crossover design, we subjected participants to 3 weeks o

215 r time-controlled studies with nonrandomized crossover design were selected for diabetic nephropathy.

216 gression models under a time-stratified case-crossover design were used to study the relationship bet

217 sly (18.4 micromol) to 6 healthy adults in a crossover design with > or =2 wk between each biotin adm

218 retention was tested in a randomized-order, crossover design with 2 concentrations of sodium-1.30 g/

219 5 human subjects were tested in a randomized crossover design with 4 breads: white-wheat bread low in

220 or a green tea extract supplement in a 3 x 3 crossover design with a 1-wk washout period in between t

221 of leptin (Wt(-10%leptin)) in a single-blind crossover design with a 2-wk washout period between trea

222 bo daily for 12 wk according to a randomized crossover design with a 4-wk washout.

223 t men were studied using a randomized 5-week crossover design with a 5-week washout period.

224 ontrolled trials have used a within-subject, crossover design with an inactive placebo as the control

225 a double-blind randomized placebo-controlled crossover design with an integrated Stop-Signal and NoGo

226 y for 1 month, compared in a random-sequence crossover design with an otherwise identical 2 h of indu

227 a maintenance diet, they were provided in a crossover design with either a vegetarian HPWL (Soy-HPWL

228 aging study used a double-blinded randomized crossover design with low-frequency inhibition trials di

229 ouble-blind placebo-controlled, three-period crossover design with naltrexone (NTX; 25 mg OD for 2 da

230 The study used a randomized, crossover design with seven subjects.

231 y-old youth were studied in a within-subject crossover design with three 3-wk phases: baseline, incre

232 randomized, double-blind, placebo-controlled crossover design with two 4-week periods of treatment, s

233 The study was a randomized crossover design with two 8-wk treatment periods.

234 andomized, double-blind, placebo-controlled, crossover design with two separate experimental sessions

235 ouble-blind, placebo-controlled, parallel or crossover designs with benzodiazepines or zolpidem in ad

236 rasted, and comparisons between parallel and crossover designs with equivalence testing are discussed

237 We used a prospective, nested case-crossover design within the Physicians' Health Study to